Search

Your search keyword '"Djezzar, Samira"' showing total 132 results
Start Over Author "Djezzar, Samira"
132 results on '"Djezzar, Samira"'

1. Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study

Author

Aquizerate, Aurélie, Laforgue, Edouard-Jules, Istvan, Marion, Rousselet, Morgane, Gérardin, Marie, Jouanjus, Emilie, Libert, Frédéric, Caous, Anne-Sylvie, Djezzar, Samira, Boucher, Alexandra, Daveluy, Amélie, Eiden, Céline, Fauconneau, Bernard, Fournier-Choma, Christine, Gibaja, Valérie, Lacroix, Clémence, Lapeyre-Mestre, Maryse, Le Boisselier, Reynald, Revol, Bruno, Guerlais, Marylène, and Victorri-Vigneau, Caroline

Published
2023
Full Text
View/download PDF

8. Évaluation du mésusage de l’alprazolam : données du réseau français d’addictovigilance

Author

Diaz, Laurine, primary, Eiden, Céline, additional, Jouanjus, Emilie, additional, Frauger, Elisabeth, additional, Fouilhé, Nathalie, additional, Djezzar, Samira, additional, Gibaja, Valérie, additional, Boucher, Alexandra, additional, Leboisselier, Reynald, additional, Libert, Frédéric, additional, Caous, Anne-Sylvie, additional, Monzon, Emilie, additional, Guerlais, Marylène, additional, Daveluy, Amélie, additional, Fauconneau, Bernard, additional, and Peyrière, Hélène, additional

Published
2022
Full Text
View/download PDF

9. Diazépam : résultats de la première enquête d’addictovigilance (2011–2020)

Author

Daveluy, Amélie, primary, Fouilhé, Nathalie, additional, Peyrière, Hélène, additional, Gibaja, Valérie, additional, Libert, Frédéric, additional, Caous, Anne-Sylvie, additional, Fauconneau, Bernard, additional, Leboisselier, Reynald, additional, Chevallier, Cécile, additional, Monzon, Emilie, additional, Ponte, Camille, additional, Djezzar, Samira, additional, Guerlais, Marylène, additional, Frauger, Elisabeth, additional, and Miremont-Salamé, Ghada, additional

Published
2022
Full Text
View/download PDF

14. Descriptive analysis of sickle cell patients living in France

Author

Gerardin, Marie, Rousselet, Morgane, Couec, Marie-Laure, Masseau, Agathe, Guerlais, Marylène, Authier, Nicolas, Deheul, Sylvie, Roussin, Anne, Micallef, Joelle, Djezzar, Samira, Feuillet, Fanny, Jolliet, Pascale, Victorri-Vigneau, Caroline, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques

Subjects
MESH: Adolescent, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Analgesics, MESH: Psychotropic Drugs, [SDV]Life Sciences [q-bio], MESH: Child, Preschool, MESH: Quality of Life, MESH: Adult, MESH: Pain Measurement, MESH: Male, MESH: France, MESH: Cross-Sectional Studies, MESH: Drug Prescriptions, MESH: Young Adult, MESH: Severity of Illness Index, MESH: Child, MESH: Pain, MESH: Anemia, Sickle Cell, MESH: Female, MESH: Pain Management, MESH: Treatment Outcome
Abstract

International audience; Background Sickle cell disease (SCD) induces chronic haemolytic anaemia and intermittent vaso-occlusion that results in tissue ischaemia causing acute, severe pain episodes that can lead to frequent hospitalizations. These consequences can have repercussions on family, social, school and/or professional life. Here, we present some of the results of the PHEDRE study (Pharmacodépendance Et DREpanocytose—drug dependence and sickle-cell disease), which is the largest study of patients with SCD in France. This paper intends to describe characteristics of the French SCD population. We also aimed to assess the impact of the disease on the lives of patients using objective and subjective variables. Methods The PHEDRE study was a national multicentric observational study. Adults, adolescents and children with a confirmed SCD diagnosis were included in the study by their referring doctor. Then, they were interviewed by phone about their socioeconomic status, about the impact of the disease on their lives and about their analgesic and psychoactive drug use. Results The study population consisted of 872 patients (28% were minors). Seventy-two percent of adults were active, and all minors were in school. Many patients presented criteria of severe SCD. Seventy-five percent were homozygous SS, 15% were double heterozygotes SC and 8% were heterozygotes Sβthal, 87% received specific treatment, 58% were hospitalized at least once for vaso-occlusive crisis in the past 12 months, and the number of analgesic drugs taken averaged 3.8. Seventy-five percent of patients reported academic or professional consequences related to their SCD, and 52% reported social consequences. Conclusions The impact of SCD on patients’ lives can be significant, nevertheless their social integration seems to be maintained. We highlighted respect of recommendations regarding analgesic treatments and only a few patients used tobacco, alcohol or cannabis. Trial registration Clinical Trials, NCT02580565 ; https://clinicaltrials.gov/ Registered 16 October 2015.

Published
2021

19. List of Contributors

Author

Alvarez, Jean-Claude, primary, Anger, Jean-Pierre, additional, Brunet, Bertrand, additional, Chèze, Marjorie, additional, Deveaux, Marc, additional, Djezzar, Samira, additional, Dumestre-Toulet, Véronique, additional, Eysseric-Guérin, Hélène, additional, Gaulier, Jean-Michel, additional, Goullé, Jean-Pierre, additional, Guerbet, Michel, additional, Hoizey, Guillaume, additional, Humbert, Luc, additional, Kintz, Pascal, additional, Lemaire-Hurtel, Anne-Sophie, additional, Lhermitte, Michel, additional, Mura, Patrick, additional, Pelissier, A.L., additional, Pépin, Gilbert, additional, RAUL, Jean-Sébastien, additional, Richard, Nathalie, additional, Saussereau, Elodie, additional, Staub, Christian, additional, and Spörri, Aline Staub, additional

Published
2014
Full Text
View/download PDF

24. Chemsex practice in France: An update in Addictovigilance data.

Author

Batisse, Anne, Eiden, Céline, Deheul, Sylvie, Monzon, Emilie, Djezzar, Samira, and Peyrière, Hélène

Subjects
PHARMACOEPIDEMIOLOGY, HIV, SUBSTANCE abuse, HEPATITIS C
Abstract

Background: Complications related to Chemsex practice (consumption of psychoactive substances in sexual context) were first assessed by the French Addictovigilance Network in 2014. In response to the deaths reported in 2016, a new expert report was commissioned to update the complications and evolution of Chemsex‐related practices in France. Methods: Between January 2008 and August 2017, all Chemsex cases collected through the French Addictovigilance Network's epidemiological tools were analyzed. Comparison of data between two periods (before and after 2014) was performed to assess the evolution of practices. Results: Over the entire survey period, 235 Chemsex cases were identified, all of them in men, with a mean ± SD age of 39 ± 11 years, including 24 deaths (10.2%). An increase in the number of reported cases was observed from one in 2008 to 50 in the first 8 months of 2017. The main medical histories include human immunodeficiency virus (HIV; 45%) and hepatitis C (20%) infections, and substance use disorders (36%). In those 235 cases, 345 psychoactive substances were identified, mainly cathinones. Polydrug use was reported in 75% of cases. The main complications were substance use disorders (63%), acute neurological or cardiovascular intoxications (50%), various psychiatric disorders (39%), and viral and bacterial infections (18%). γ‐Butyrolactone (GBL) was present in 95% of comas. An increase in the number of deaths was observed during the survey period. Conclusion: The French Addictovigilance Network, via this pharmacoepidemiological surveillance, warns public health authorities in order to support harm reduction programs and the management of Chemsexers. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007–2019).

Author

Perri-Plandé, Joelle, Miremont-Salamé, Ghada, Micallef, Joëlle, Herman, Cameron, Baumevieille, Marie, Abriat, Frédéric, Lapeyre-Mestre, Maryse, Haramburu, Françoise, Daveluy, Amélie, The French Addictovigilance Network, Fouilhé, Nathalie, Boucher, Alexandra, Pain, Stéphanie, Djezzar, Samira, Peyrière, Hélène, Gérardin, Marie, Fournier-Choma, Christine, Gibaja, Valérie, Boisselier, Reynald, and Caous, Anne-Sylvie

Subjects
NARCOTIC analgesics, DRUG prescribing, MORPHINE, OPIOIDS, OXYCODONE
Abstract

Introduction: Analgesics are among the most widely used drugs worldwide. This study describes the population treated with narcotic analgesics, their therapeutic indications and how the data have evolved over a decade. Methods: A cross-sectional, national, multicentre survey study was conducted that included surveys taken every year from 2007 to 2019 in a national sample of 1500 randomly selected dispensing pharmacies. Results: The mean age of patients, mostly women (around 60%), remained stable over the study period (63.2 ± 17.1 years in 2007, 68.2 ± 17.2 years in 2019). The proportion of patients treated for more than 3 months increased from 2007 to 2019. Most prescriptions involved morphine, oxycodone and fentanyl (98.5% of all prescriptions in 2019). Morphine prescriptions dropped dramatically from 49.6% (2007) to 32.3% (2019) of the total narcotic analgesics. Fentanyl prescriptions varied from 40.1% in 2007 to 32.2% in 2019. Prescriptions of oxycodone, regardless of the indication, increased steadily from 2007, from 8.3 to 34% in 2019, becoming the most prescribed narcotic analgesic for the first time since the beginning of the survey. Conclusions: This study demonstrates how narcotic opioids are prescribed, thanks to the active participation of health professionals, and confirms the striking increase in the prescription of oxycodone. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. ChemSex, NPS et réduction des risques : intérêt de l’analyse de produits

Author

Batisse, Anne, primary, Chevallier, Cécile, additional, Richeval, Camille, additional, Labrouve, Vincent, additional, Martinez, Magalie, additional, Allorge, Delphine, additional, Gregoire, Muriel, additional, Batel, Philippe, additional, Marillier, Maude, additional, Nefau, Thomas, additional, Gaulier, Jean-Michel, additional, and Djezzar, Samira, additional

Published
2018
Full Text
View/download PDF

35. « Research chemicals » benzodiazepines : analyse des données des centres français d’addictovigilance et revue de la littérature

Author

Serre, Anaïs, primary, Eiden, Céline, additional, Gerardin, Marie, additional, Caoux, Anne-Sylvie, additional, Chevallier, Cécile, additional, Daveluy, Amélie, additional, Kahn, Jean-Pierre, additional, Leboisselier, Reynald, additional, Revol, Bruno, additional, Pizzoglio, Véronique, additional, Pochard, Liselotte, additional, Monzon, Emilie, additional, Djezzar, Samira, additional, and Peyrière, Hélène, additional

Published
2018
Full Text
View/download PDF

36. Mephenesin

Author

Chevallier, Cecile, primary, Batisse, Anne, additional, Fortias, Maeva, additional, and Djezzar, Samira, additional

Published
2018
Full Text
View/download PDF

38. CHEMSEX, NPS & risk reduction management: Preliminary results of a pilot study

Author

Marillier, Maude, primary, Batisse, Anne, additional, Richeval, Camille, additional, Labrouve, Vincent, additional, Martinez, Magali, additional, Allorge, Delphine, additional, Gregoire, Muriel, additional, Batel, Philippe, additional, Nefau, Thomas, additional, Chevallier, Cécile, additional, Gaulier, Jean-Michel, additional, and Djezzar, Samira, additional

Published
2017
Full Text
View/download PDF

39. “NRG-3”: What's in this?

Author

Batisse, Anne, primary, Marillier, Maude, additional, Chevallier, Cécile, additional, Bourgogne, Emmanuel, additional, Grégoire, Muriel, additional, Laprévote, Olivier, additional, and Djezzar, Samira, additional

Published
2017
Full Text
View/download PDF

41. Abus et intoxication mortelle à la méphénésine

Author

El Balkhi, Souleiman, primary, Djezzar, Samira, additional, Poncelet, Lauranne, additional, Dulaurent, Sylvain, additional, Morichon, Julien, additional, Coutaz-Fluck, Caroline, additional, Sainte-Laudy, Jean, additional, Paraf, François, additional, and Saint-Marcoux, Franck, additional

Published
2016
Full Text
View/download PDF

44. Mephenesin Dependence

Author

Djezzar, Samira, primary, Vorspan, Florence, additional, Chataigner, Dominique, additional, Burin, Emmanuel, additional, Garnier, Robert, additional, and Lépine, Jean-Pierre, additional

Published
2012
Full Text
View/download PDF

45. Le dispositif français d’addictovigilance

Author

Djezzar, Samira

Abstract

L’addictovigilance est la surveillance des cas d’abus et de dépendance liés à la prise de toute substance ayant un effet psychoactif addictogène à l’exclusion de l’alcool éthylique et du tabac. Elle est assurée par un réseau national de centres qui permet aux autorités de prendre des mesures pour préserver la santé publique, de la surveillance ou l’encadrement des conditions d’utilisation des médicaments psychoactifs à leur classement sur la liste des stupéfiants et psychotropes. Ce réseau soutient les professionnels dans la prise en charge des patients et l’évaluation pharmacoclinique des troubles liés à l’usage de ces produits. Il est l’interlocuteur privilégié des patients, usagers et victimes d’actes criminels commis sous influence de ces substances.

Published
2023
Full Text
View/download PDF

50. La méphédrone : une designer drugd’usage récent en France

Author

Debruyne, Danièle, Courné, Marie-Anne, Le Boisselier, Reynald, Djezzar, Samira, Gérardin, Marie, Boucher, Alexandra, Karila, Laurent, Coquerel, Antoine, and Mallaret, Michel

Abstract

De plus en plus de designer drugssont utilisées en remplacement des stimulants classiques type cocaïne, amphétamine, 3,4-méthylène-dioxy-méthylamphétamine (MDMA ou ecstasy)… Contrairement aux produits classés comme stupéfiants, ces nouvelles substances peuvent être détenues et consommées sans risque vis-à-vis de la loi. Parmi eux, la méphédrone (4-méthylmethcatinone), appartenant à la famille des cathinones, est récemment apparue sur le territoire français. Les effets positifs ressentis par les usagers sont une euphorie et une action entactogène favorisant la discussion avec les autres, l’empathie et l’expression. Les effets négatifs sont une sensation de grande dépendance avec une envie majorée de consommation d’alcool et de tabac. Les effets indésirables sont nombreux et divers au niveau du système nerveux central, digestif, cardiovasculaire… Des cas de décès ont été rapportés, souvent en association avec un autre produit. La méphédrone a été récemment classée comme stupéfiant dans différents pays européens dont la France.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results